PMN
ProMIS Neurosciences, Inc.
Price Chart
Latest Quote
$10.54
+0.16 (+1.54%)
Current Price
| Previous Close | $10.38 |
| Open | $10.32 |
| Day High | $10.75 |
| Day Low | $10.32 |
| Volume | 5,263 |
Stock Information
| Shares Outstanding | 8.97M |
| Cash Equivalents | $63.85M |
| Net Income | $-40.62M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $94.52M |
| EPS (TTM) | $-18.45 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $30.67M |
| Income | $-40.62M |
| Book/sh | $6.77 |
| Cash/sh | $7.12 |
| Employees | 10 |
Financial Ratios
| Quick Ratio | 9.69 |
| Current Ratio | 9.92 |
Returns & Margins
| ROA | -63.00% |
| ROE | -115.73% |
Ownership
| Insider Ownership | 11.87% |
| Institutional Ownership | 74.37% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -17.28 |
| P/B | 1.56 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $34.47 |
Technical Indicators
| SMA20 | $10.26 |
| SMA50 | $10.77 |
| SMA200 | $11.73 |
| RSI | 47.03 |
| ATR | 0.7743 |
| Shares Float | 4.60M |
| Short Float | 2.12% |
| Short Ratio | 6.21 |
| Volatility | -0.17 |
| Rel Volume | 0.29 |
Performance History
| Week | -1.50% |
| Month | -1.03% |
| Quarter | -42.12% |
| 6 Months | +12.85% |
| YTD | +47.62% |
| Year | -13.96% |
| 3 Years | -91.43% |
| 5 Years | -96.49% |
| 10 Years | -91.22% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $10.54 | 5,900 |
| 2026-06-17 | $10.38 | 12,500 |
| 2026-06-16 | $10.16 | 17,000 |
| 2026-06-15 | $10.05 | 6,800 |
| 2026-06-12 | $10.35 | 17,700 |
| 2026-06-11 | $10.70 | 6,000 |
| 2026-06-10 | $10.20 | 25,500 |
| 2026-06-09 | $9.75 | 11,300 |
| 2026-06-08 | $9.71 | 12,700 |
| 2026-06-05 | $9.13 | 32,400 |
| 2026-06-04 | $9.73 | 14,400 |
| 2026-06-03 | $9.65 | 38,100 |
| 2026-06-02 | $10.15 | 38,700 |
| 2026-06-01 | $10.41 | 15,100 |
| 2026-05-29 | $10.81 | 46,600 |
| 2026-05-28 | $10.87 | 13,100 |
| 2026-05-27 | $10.48 | 11,900 |
| 2026-05-26 | $10.36 | 33,800 |
| 2026-05-22 | $10.98 | 29,400 |
| 2026-05-21 | $10.85 | 21,300 |
| 2026-05-20 | $10.60 | 6,500 |
| 2026-05-19 | $10.65 | 13,700 |
About ProMIS Neurosciences, Inc.
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
đ° Latest News
All You Need to Know About Promis Neurosciences (PMN) Rating Upgrade to Buy
Zacks âĸ 2026-06-12T16:00:03Z
Wall Street Analysts Think Promis Neurosciences (PMN) Could Surge 231.78%: Read This Before Placing a Bet
Zacks âĸ 2026-06-12T13:55:02Z
Phoenix Mecano's (VTX:PMN) Conservative Accounting Might Explain Soft Earnings
Simply Wall St. âĸ 2026-04-30T05:03:34Z
Five US Stocks See Over $185M in Insider Buying, with Soho House and WR Berkley Leading the Pack
24/7 Wall St. âĸ 2026-02-09T13:35:28Z
An Intrinsic Calculation For Phoenix Mecano AG (VTX:PMN) Suggests It's 44% Undervalued
Simply Wall St. âĸ 2026-01-18T07:23:41Z
Phoenix Mecano (VTX:PMN) shareholders have earned a 15% CAGR over the last three years
Simply Wall St. âĸ 2026-01-01T04:07:46Z
Is Phoenix Mecano AG's (VTX:PMN) Latest Stock Performance Being Led By Its Strong Fundamentals?
Simply Wall St. âĸ 2025-12-12T09:00:19Z
Can ProMIS Neurosciences (NASDAQ:PMN) Afford To Invest In Growth?
Simply Wall St. âĸ 2025-11-15T12:47:06Z
Phoenix Mecano (VTX:PMN) Might Have The Makings Of A Multi-Bagger
Simply Wall St. âĸ 2025-11-07T10:36:53Z
With 39% ownership, Phoenix Mecano AG (VTX:PMN) insiders have a lot at stake
Simply Wall St. âĸ 2025-09-22T06:50:43Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $0 | $76,775 | $201,390 | $282,064 |
| Total Expenses | $40,167,308 | $16,827,478 | $14,262,733 | $23,379,912 |
| Other Income Expense | $448,161 | $19,683,126 | $1,251,641 | $5,599,713 |
| Other Non Operating Income Expenses | $442,569 | $-2,898,351 | $384,903 | $115,525 |
| Net Non Operating Interest Income Expense | $0 | $-76,775 | $-201,390 | $-282,064 |
| Interest Expense Non Operating | $0 | $76,775 | $201,390 | $282,064 |
| Operating Expense | $40,167,308 | $16,827,478 | $14,262,733 | $23,379,912 |
| General And Administrative Expense | $6,787,987 | $6,189,502 | $6,379,568 | $7,292,744 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-39,719,147 | $2,778,873 | $-13,212,482 | $-18,062,263 |
| Net Interest Income | $0 | $-76,775 | $-201,390 | $-282,064 |
| Normalized Income | $-39,724,739 | $-16,415,382 | $-14,079,220 | $-23,546,451 |
| Net Income From Continuing And Discontinued Operation | $-39,719,147 | $2,778,873 | $-13,212,482 | $-18,062,263 |
| Total Operating Income As Reported | $-40,167,308 | $-16,827,478 | $-14,262,733 | $-23,379,912 |
| Net Income Common Stockholders | $-39,719,147 | $2,778,873 | $-13,212,482 | $-18,062,263 |
| Net Income | $-39,719,147 | $2,778,873 | $-13,212,482 | $-18,062,263 |
| Net Income Including Noncontrolling Interests | $-39,719,147 | $2,778,873 | $-13,212,482 | $-18,062,263 |
| Net Income Continuous Operations | $-39,719,147 | $2,778,873 | $-13,212,482 | $-18,062,263 |
| Pretax Income | $-39,719,147 | $2,778,873 | $-13,212,482 | $-18,062,263 |
| Operating Income | $-40,167,308 | $-16,827,478 | $-14,262,733 | $-23,379,912 |
| Special Income Charges | - | - | $0 | $1,307,421 |
| Interest Income | - | - | - | - |
| Interest Income Non Operating | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-22.61 | $2.63 | $-26.75 | $-60.25 |
| Basic EPS | $-22.61 | $2.68 | $-26.75 | $-60.25 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $3,387,222 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-39,724,739 | $-19,725,829 | $-13,856,671 | $-23,253,171 |
| Total Unusual Items | $5,592 | $22,581,477 | $866,738 | $5,484,188 |
| Total Unusual Items Excluding Goodwill | $5,592 | $22,581,477 | $866,738 | $5,484,188 |
| EBITDA (Bullshit earnings) | $-39,719,147 | $2,855,648 | $-12,989,933 | $-17,768,983 |
| EBIT | $-39,719,147 | $2,855,648 | $-13,011,092 | $-17,780,199 |
| Diluted Average Shares | $1,756,844 | $1,058,469 | $491,708 | $300,104 |
| Basic Average Shares | $1,756,844 | $1,036,799 | $491,708 | $300,104 |
| Diluted NI Availto Com Stockholders | $-39,719,147 | $2,778,873 | $-13,212,482 | $-18,062,263 |
| Gain On Sale Of Security | $5,592 | $22,581,477 | $866,738 | $4,176,767 |
| Research And Development | $33,379,321 | $10,637,976 | $7,883,165 | $16,087,168 |
| Selling General And Administration | $6,787,987 | $6,189,502 | $6,379,568 | $7,292,744 |
| Other Gand A | $6,787,987 | $6,189,502 | $6,379,568 | $7,292,744 |
| Reconciled Depreciation | - | $0 | $21,159 | $11,216 |
| Other Special Charges | - | - | - | $-1,307,421 |
| Gain On Sale Of Ppe | - | - | - | - |
Fetched: 2026-06-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-1,258,592 | $16,488,176 | $3,753,296 | $-1,368,610 |
| Total Assets | $9,182,421 | $18,911,456 | $13,619,145 | $6,924,646 |
| Total Non Current Assets | $0 | $0 | $0 | $21,159 |
| Current Assets | $9,182,421 | $18,911,456 | $13,619,145 | $6,903,487 |
| Other Current Assets | $38,150 | $47,281 | $33,217 | $4,623 |
| Current Deferred Assets | $32,332 | $0 | $195,632 | $0 |
| Prepaid Assets | $2,925,108 | $5,461,923 | $681,155 | $920,433 |
| Receivables | $36,522 | $78,034 | $78,637 | $71,626 |
| Accrued Interest Receivable | $36,522 | $78,034 | $78,637 | $0 |
| Cash Cash Equivalents And Short Term Investments | $6,150,309 | $13,324,218 | $12,630,504 | $5,906,805 |
| Cash And Cash Equivalents | $6,116,556 | $13,291,167 | $12,598,146 | $5,875,796 |
| Cash Financial | $6,116,556 | $13,291,167 | $12,598,146 | $5,875,796 |
| Goodwill And Other Intangible Assets | - | - | $0 | $20,838 |
| Taxes Receivable | - | - | $20,485 | $71,626 |
| Other Receivables | - | - | - | - |
| Debt | ||||
| Total Debt | - | - | - | - |
| Long Term Debt And Capital Lease Obligation | - | - | - | - |
| Long Term Debt | - | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $10,441,013 | $2,423,280 | $9,865,849 | $8,272,418 |
| Total Non Current Liabilities Net Minority Interest | $29,182 | $204,855 | $516,187 | $1,859,374 |
| Derivative Product Liabilities | $0 | $5,592 | $94,185 | $1,859,374 |
| Current Liabilities | $10,411,831 | $2,218,425 | $9,349,662 | $6,413,044 |
| Payables And Accrued Expenses | $10,332,083 | $2,180,097 | $8,830,958 | $6,413,044 |
| Payables | $2,543,415 | $1,737,463 | $7,843,136 | $2,975,398 |
| Accounts Payable | $2,543,415 | $1,737,463 | $7,843,136 | $2,975,398 |
| Interest Payable | - | - | - | $0 |
| Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $-1,258,592 | $16,488,176 | $3,753,296 | $-1,347,772 |
| Total Equity Gross Minority Interest | $-1,258,592 | $16,488,176 | $3,753,296 | $-1,347,772 |
| Stockholders Equity | $-1,258,592 | $16,488,176 | $3,753,296 | $-1,347,772 |
| Gains Losses Not Affecting Retained Earnings | $-371,184 | $-371,184 | $-371,184 | $-195,369 |
| Other Equity Adjustments | $-371,184 | $-371,184 | $-371,184 | $-195,369 |
| Retained Earnings | $-130,406,220 | $-90,687,073 | $-93,465,946 | $-80,253,464 |
| Other Equity Interest | - | - | - | - |
| Long Term Equity Investment | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $2,152,397 | $1,307,567 | $755,410 | $343,171 |
| Share Issued | $2,152,397 | $1,307,567 | $755,410 | $343,171 |
| Tangible Book Value | $-1,258,592 | $16,488,176 | $3,753,296 | $-1,368,610 |
| Invested Capital | $-1,258,592 | $16,488,176 | $3,753,296 | $-1,347,772 |
| Working Capital | $-1,229,410 | $16,693,031 | $4,269,483 | $490,443 |
| Total Capitalization | $-1,258,592 | $16,488,176 | $3,753,296 | $-1,347,772 |
| Additional Paid In Capital | $129,518,812 | $107,546,433 | $97,590,426 | $79,101,061 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $29,182 | $199,263 | $422,002 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $79,748 | $38,328 | $518,704 | $0 |
| Current Accrued Expenses | $7,788,668 | $442,634 | $987,822 | $3,437,646 |
| Other Short Term Investments | $33,753 | $33,051 | $32,358 | $31,009 |
| Treasury Shares Number | - | - | $0 | - |
| Net PPE | - | - | $0 | $321 |
| Accumulated Depreciation | - | - | - | $-80,000 |
| Gross PPE | - | - | - | $80,321 |
| Other Properties | - | - | - | $61,933 |
| Machinery Furniture Equipment | - | - | - | $18,388 |
| Investments And Advances | - | - | - | - |
| Investmentsin Joint Venturesat Cost | - | - | - | - |
Fetched: 2026-06-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-28,118,579 | $-27,182,095 | $-10,843,676 | $-17,035,864 |
| Operating Activities | ||||
| Operating Cash Flow | $-28,118,579 | $-27,182,095 | $-10,843,676 | $-17,033,883 |
| Cash Flow From Continuing Operating Activities | $-28,118,579 | $-27,182,095 | $-10,843,676 | $-17,033,883 |
| Operating Gains Losses | $-5,592 | $-22,581,477 | $-868,555 | $-5,114,878 |
| Investing Activities | ||||
| Investing Cash Flow | $-702 | $-693 | $-1,349 | $-1,981 |
| Cash Flow From Continuing Investing Activities | $-702 | $-693 | $-1,349 | $-1,981 |
| Capital Expenditure | - | - | - | $-1,981 |
| Net Other Investing Changes | - | - | - | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $20,243,962 | $27,847,771 | $17,745,200 | $4,974,253 |
| Financing Cash Flow | $20,944,670 | $27,875,809 | $17,748,800 | $6,494,654 |
| Cash Flow From Continuing Financing Activities | $20,944,670 | $27,875,809 | $17,748,800 | $6,494,654 |
| Net Common Stock Issuance | $20,243,962 | $27,847,771 | $17,745,200 | $4,974,253 |
| Common Stock Issuance | $20,243,962 | $27,847,771 | $17,745,200 | $4,974,253 |
| Repurchase Of Capital Stock | - | - | - | - |
| Other | ||||
| Interest Paid Supplemental Data | $0 | $76,775 | $201,390 | $87,069 |
| End Cash Position | $6,116,556 | $13,291,167 | $12,598,146 | $5,875,796 |
| Beginning Cash Position | $13,291,167 | $12,598,146 | $5,875,796 | $16,943,905 |
| Changes In Cash | $-7,174,611 | $693,021 | $6,903,775 | $-10,541,210 |
| Proceeds From Stock Option Exercised | $700,708 | $28,038 | $3,600 | $1,520,401 |
| Net Investment Purchase And Sale | $-702 | $-693 | $-1,349 | $0 |
| Sale Of Investment | $33,051 | $32,358 | $31,009 | $31,009 |
| Purchase Of Investment | $-33,753 | $-33,051 | $-32,358 | $-31,009 |
| Change In Working Capital | $10,748,532 | $-11,729,834 | $2,944,660 | $5,402,558 |
| Change In Payables And Accrued Expense | $8,193,406 | $-7,131,237 | $3,131,981 | $5,721,305 |
| Change In Accrued Expense | $7,387,454 | $-1,025,564 | $-1,831,237 | $3,045,612 |
| Change In Payable | $805,952 | $-6,105,673 | $4,963,218 | $2,675,693 |
| Change In Account Payable | $805,952 | $-6,105,673 | $4,963,218 | $2,675,693 |
| Change In Prepaid Assets | $2,555,126 | $-4,598,597 | $-187,321 | $-318,747 |
| Stock Based Compensation | $857,628 | $825,808 | $271,542 | $487,630 |
| Gain Loss On Investment Securities | $-5,592 | $-22,581,477 | $-866,738 | $-4,112,864 |
| Net Income From Continuing Operations | $-39,719,147 | $2,778,873 | $-13,212,482 | $-18,062,263 |
| Effect Of Exchange Rate Changes | - | $0 | $-181,425 | $-526,899 |
| Other Non Cash Items | - | $3,524,535 | - | $241,854 |
| Depreciation Amortization Depletion | - | $0 | $21,159 | $11,216 |
| Depreciation And Amortization | - | $0 | $21,159 | $11,216 |
| Amortization Cash Flow | - | $0 | $20,838 | $5,072 |
| Amortization Of Intangibles | - | $0 | $20,838 | $5,072 |
| Depreciation | - | $0 | $321 | $6,144 |
| Net Foreign Currency Exchange Gain Loss | - | $0 | $-1,817 | $305,407 |
| Net PPE Purchase And Sale | - | - | $0 | $-1,981 |
| Purchase Of PPE | - | - | $0 | $-1,981 |
| Issuance Of Debt | - | - | - | $0 |
| Net Issuance Payments Of Debt | - | - | - | $0 |
| Net Long Term Debt Issuance | - | - | - | $0 |
| Long Term Debt Issuance | - | - | - | $0 |
| Sale Of PPE | - | - | - | $0 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
| Common Stock Payments | - | - | - | - |
| Net Business Purchase And Sale | - | - | - | - |
| Sale Of Business | - | - | - | - |
| Change In Other Working Capital | - | - | - | - |
| Change In Receivables | - | - | - | - |
Fetched: 2026-06-18